Baird downgraded Intra-Cellular (ITCI) to Neutral from Outperform with a $132 price target after Johnson & Johnson (JNJ) agreed to acquire all outstanding shares of Intra-Cellular for $132 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
- Biotech Alert: Searches spiking for these stocks today
- Intra-Cellular downgraded to Neutral from Overweight at Cantor Fitzgerald
- Intra-Cellular downgraded to Hold from Buy at Needham
- Intra-Cellular downgraded to Equal Weight from Overweight at Morgan Stanley